大肠癌患者血清及癌组织中生长抑素水平测定的临床意义

检测４３例大肠癌患者血清、癌组织及癌旁粘膜中生长抑素水平。结果大肠癌患者术前空腹血清生长抑素含量明显低于对照组（Ｐ＜０．００１），根治术后明显高于术前（Ｐ＜０．０１），但仍明显低于对照组（Ｐ＜０．００１）。大肠癌组织中生长抑素含量明显低于正常大肠粘膜（Ｐ＜０．００１），亦低于癌旁粘膜（Ｐ＜０．００１），但血清及癌组织中生长抑素水平与大肠癌组织学类型及Ｄｕｋｅ＇ｓ分期均无显著关系。提示生长抑素对大肠癌的生长具有负性调控作用，从而为大肠癌患者应用生长抑素类药物治疗提供实验依据。

THE CLINICAL SIGNWICANCE OF MEASUREMENT OF SOMATOSTATIN LEVELS IN SERUM AND CANCER TISSUE OF PATIENTS WITH LARGE INTESTINE CARCINOMA

The somatostatin levels in serum,cancer tissue and its adjacent mucosas were measured in 43 patients with large intestine carcinoma(LIC). The results showed that the somatostatin level in serum of patients with LIC before operation was obviously lower than that in the control group (P< 0.001)and after radical operation, it was markedly higher than the preoperative levels (P<0. 01 ),but still lower than the control value(P<0. 001). The somatostatin level in cancer tissue was evidently lower than that in its adjacent mucosas (P<0. 001 )and in normal mucosa(P<0. 001). There was no significant correlation between the somatostatin level in serum or carcinoma tissue and the Duke's stage or pathological types of the carcinoma tissue. The results indicate that the somatostatin has a negative modulating effect on the growth of large intestinal carcinomas,thus provides an experimental basis for the treatment of large intestinal carcinomas with drugs such as somatostatin.